Immunodiagnostics Market

Market Overview:

The global immunodiagnostics market size reached US$ 17.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 27.2 Billion by 2028, exhibiting a growth rate (CAGR) of 7.72% during 2023-2028. 

Immunodiagnostics refers to an in-vitro diagnostic technology that uses antigen-antibody reaction for the detection of infectious and chronic diseases. It involves the use of radiological, fluorescent or color-forming enzymes and probes for the identification of antibodies that aid in enhancing the targeting range to identify disease progression. Immunodiagnostics also uses various reagents, instruments and software-based solutions for enzyme-linked immunosorbent assay, chemiluminescence, radioimmunoassay and rapid testing. These solutions are widely used for diagnosing diseases, such as cancer and autoimmune, respiratory, endocrine and oncological disorders, along with forensic psychology and environmental and food analysis. As a result, immunodiagnostics finds extensive applications across hospitals, clinical laboratories and research and academic institutes.

Immunodiagnostics Market Trends:

The increasing prevalence of chronic medical ailments and infections among the masses is one of the key factors driving the market growth. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the growth of the market. There is also an escalating awareness among the consumers regarding the available treatment alternatives for ailments, such as hepatitis B, diabetes and cancer, which is positively impacting the demand for immunodiagnostics kits, assays and analyzers. Additionally, various technological advancements, such as the development of next-generation immunodiagnostics platforms, are anticipated to drive the market toward growth. These advanced point-of-care testing (POCT) systems offer enhanced diagnostic facilities for sepsis, acute cardiac infractions and other medical disorders with higher mortality rates. Other factors, including the increasing requirement for personalized medicines among the masses, along with extensive improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global immunodiagnostics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, technology, application and end user.

Breakup by Product:

• Reagents
• Instruments
• Software and Services
   

Breakup by Technology:

• Enzyme-Linked Immunosorbent Assay
• Chemiluminescence Immunoassay
• Fluorescent Immunoassay
• Radioimmunoassay
• Rapid Test
• Others
   

Breakup by Application:

• Infectious Diseases
• Oncology and Endocrinology
• Hepatitis and Retrovirus
• Bone and Mineral
• Autoimmunity
• Cardiac Biomarker
• Others
   

Breakup by End User:

• Hospitals
• Clinical Laboratories
• Academic and Research Centers
• Pharmaceutical and Biotechnology Industry
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arkray Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche AG, Immunodiagnostic Systems Holdings PLC, Johnson & Johnson, Siemens AG, Sysmex Corporation and Thermo Fisher Scientific Inc.

Report Coverage: